We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Genetic Locus Associated with the Tyrosine Phosphokinase Gene Is an OCD Biomarker

By LabMedica International staff writers
Posted on 26 May 2014
A genetic locus located near the gene that encodes the enzyme tyrosine phosphokinase (PTPRD) was found to be associated significantly with obsessive-compulsive disorder (OCD).

The protein encoded by the PTPRD gene is a member of the protein tyrosine phosphatase (PTP) family. More...
PTPs are known to be signaling molecules that regulate a variety of cellular processes including cell growth, differentiation, mitotic cycle, and oncogenic transformation. PTPRD is regarded as a receptor-type PTP, since it contains an extracellular region, a single transmembrane segment, and two tandem intracytoplasmic catalytic domains.

OCD is a psychiatric condition characterized by intrusive thoughts and urges and repetitive, intentional behaviors that cause significant distress and impair functioning. Investigators at Johns Hopkins University (Baltimore, MD, USA) are participants in The OCD Collaborative Genetics Association Study (OCGAS), which monitors a large group of comprehensively assessed OCD patients with an early age of OCD onset.

For the current study the investigators conducted a genome-wide association study (GWAS), scanning the genomes of more than 1,400 people with OCD and an additional 1,000 close relatives.

A GWAS is an examination of many common genetic variants in different individuals to see if any variant is associated with a trait. A GWAS typically focuses on associations between single-nucleotide polymorphisms (SNPs) and traits such as major diseases. These studies normally compare the DNA of two groups of participants: people with the disease (cases) and similar people without (controls). Each person gives a sample of DNA, from which millions of genetic variants are read using SNP arrays. If one type of the variant is more frequent in people with the disease, the SNP is said to be "associated" with the disease. The associated SNPs are then considered to mark a region of the human genome which influences the risk of disease. In contrast to methods which specifically test one or a few genetic regions, a GWAS investigates the entire genome. A GWAS identifies SNPs and other variants in DNA which are associated with a disease, but cannot on its own specify which genes cause the illness.

Results of the GWAS revealed a link to OCD on chromosome 9 near the PTPRD gene. Presynaptic PTPRD promotes the differentiation of glutamatergic synapses and interacts with SLITRK3. Members of the SLITRK family, such as SLITRK3, are integral membrane proteins with two N-terminal leucine-rich repeat domains similar to those of SLIT proteins. Most SLITRKs, including SLITRK3, also have C-terminal regions that share homology with neurotrophin receptors. SLITRKs are expressed predominantly in neural tissues and have neurite-modulating activity. Both PTPRD and SLITRK3 regulate the development of inhibitory GABAergic synapses.

"If this finding is confirmed, it could be useful," said senior author Dr. Gerald Nestadt, professor of psychiatry and behavioral sciences at Johns Hopkins University. "We might ultimately be able to identify new drugs that could help people with this often disabling disorder, one for which current medications work only 60% to 70% of the time."

"OCD research has lagged behind other psychiatric disorders in terms of genetics," said Dr. Nestadt. "We hope this interesting finding brings us closer to making better sense of it and helps us find ways to treat it."

The study was published in the May 13, 2014, online edition of the journal Molecular Psychiatry.

Related Links:
Johns Hopkins University



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.